Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
General thiol-containing proteins represent a broad and heterogeneous class of proteins defined by the presence of reactive sulfhydryl (-SH) groups, typically located on cysteine residues. These thiols are essential for a wide array of biological processes, including the formation of stabilizing disulfide bridges, the coordination of metal ions, and the execution of catalytic cycles in enzymes such as cysteine proteases and tyrosine phosphatases (Source: PubMed, PMID: 23517511). Furthermore, protein thiols serve as critical sensors and effectors in redox signaling, protecting cells against oxidative damage by acting as sacrificial targets for reactive oxygen species (Source: NIH/PMC, PMC3603499). In clinical contexts, the modification of these groups is a hallmark of various pathologies, including cancer, where altered redox states promote tumor progression, and neurodegenerative diseases characterized by oxidative stress (Source: Nature Reviews Drug Discovery). While certain drugs like auranofin or N-acetylcysteine interact with this class to modulate cellular redox balance, the lack of specificity inherent in targeting general thiols often leads to significant off-target effects and systemic toxicity (Source: PubChem). Consequently, modern drug development focuses on targeting specific cysteine residues within individual proteins rather than the entire class of thiol-containing proteins. The reactivity of these groups also makes them primary targets for environmental toxins, such as heavy metals, which can disrupt protein function across multiple systems (Source: Wikipedia).
Covalent modification or oxidation of sulfhydryl groups on cysteine residues, which can inhibit enzyme activity, disrupt structural integrity, or alter cellular redox signaling pathways.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on General thiol-containing proteins.